



IBL HEALTHCARE LIMITED**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-audited)****FOR THE PERIOD ENDED MARCH 31, 2023**

	Note	Quarter ended		Nine-months ended	
		March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
------(Rs. in '000)-----					
Revenue from contracts with customers	12	985,087	900,093	3,010,903	2,673,458
Cost of Sales		(663,879)	(624,935)	(2,020,158)	(1,787,607)
Gross Profit		321,209	275,158	990,746	885,851
Other income / (loss)	13	62,765	3,382	14,901	(6,325)
Marketing and distribution expenses		(189,758)	(140,132)	(485,320)	(423,962)
Administrative and general expenses		(23,739)	(23,800)	(72,799)	(70,155)
Finance cost	14	(19,003)	(5,133)	(50,017)	(16,811)
Profit before taxation		151,474	109,475	397,511	368,598
Income tax expense		(53,899)	(30,025)	(128,680)	(114,852)
Profit after taxation		97,576	79,450	268,832	253,746
Other comprehensive income		-	-	-	-
Total comprehensive income		97,576	79,450	268,832	253,746
			(Re-stated)		(Re-stated)
Earnings per share - basic and diluted		1.37	1.11	3.77	3.55

The annexed notes 1 to 16 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer